Using tumor DNA to guide rectal cancer treatment
Part of Cancer, Digestive system clinical trials.
This study looks at whether a blood test that finds tumor DNA can help doctors choose the best treatment for rectal cancer, possibly allowing some patients to avoid surgery. It tests different chemotherapy and radiation combinations to see if the cancer disappears completely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that has grown into the bowel wall (T3 or T4) or spread to nearby lymph nodes, but has not spread to other organs.
- You are 18 years or older and are generally able to care for yourself (ECOG 0-2).
- You can have at least 3 months of chemotherapy (like FOLFOX or CAPOX) and radiation therapy to the pelvis.
- You have a tumor sample available from a previous biopsy or are willing to have a new biopsy.
- You are not pregnant or breastfeeding, and you do not have another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.
This trial tests whether checking for tumor DNA in your blood after surgery can help decide if you need additional chemotherapy. If the test finds cancer DNA, you may get chemo to lower the risk of the cancer coming back.
This study looks at whether a genetic test on a small sample of your tumor can predict how well you will respond to chemotherapy and radiation before surgery. This might help doctors choose the best treatment for you.
This trial uses a special DNA blood test (circulating tumor DNA) to help guide chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to improve outcomes by tailoring treatment based on the DNA signals from the tumor.
This trial uses a personalized blood test (ctDNA-MRD) to see how well neoadjuvant therapy works for rectal cancer. If you have stage II or III rectal cancer that can be surgically removed, this study might help guide your treatment.
This study looks at a blood test (ctDNA, a way to detect cancer DNA in the bloodstream) to help doctors choose treatment that may spare organs for people with stage II–III rectal cancer. You may be followed to see how well the blood test can guide treatment decisions.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.